BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes in patients with Barrett's oesophagus. METHODS: The Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial had a 2 × 2 factorial design and was done at 84 centres in the UK and one in Canada. Patients with Barrett's oesophagus of 1 cm or more were randomised 1:1:1:1 using a computer-generated schedule held in a central trials unit to receive high-dose (40 mg twice-daily) or low-dose (20 mg once-daily) PPI, with or without aspirin (300 mg per day in the ...
Background: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Background: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barre...
textabstractObjectives: Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs...
Background: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and ...
Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide a...
Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide a...
Background: Barrett’s esophagus is the most significant predictor of the development of esophageal a...
BACKGROUND: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Oesophageal cancer worldwide is the eighth commonest cancer and carries a poor prognosis. Barrett’s ...
Gastrointestinal cancer accounts for approximately 25 of all cancers and approximately 9 of all deat...
Despite advances in diagnosis and therapy, esophageal adenocarcinoma remains an aggressive and usual...
Barrett’s esophagus is the precursor lesion of esophageal adenocarcinoma, a tumor with increasing i...
Esophageal adenocarcinoma (EA) is the sixth most common cause of global cancer death. We rely on end...
Barrett's oesophagus normally affects the distal oesophagus when metaplastic columnar lined epitheli...
AIM: Our main objectives were to evaluate the influence of two-year proton pump inhibitors (PPI) the...
Background: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Background: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barre...
textabstractObjectives: Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs...
Background: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and ...
Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide a...
Background: Oesophageal adenocarcinoma (OA) is the sixth commonest cause of cancer death worldwide a...
Background: Barrett’s esophagus is the most significant predictor of the development of esophageal a...
BACKGROUND: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Oesophageal cancer worldwide is the eighth commonest cancer and carries a poor prognosis. Barrett’s ...
Gastrointestinal cancer accounts for approximately 25 of all cancers and approximately 9 of all deat...
Despite advances in diagnosis and therapy, esophageal adenocarcinoma remains an aggressive and usual...
Barrett’s esophagus is the precursor lesion of esophageal adenocarcinoma, a tumor with increasing i...
Esophageal adenocarcinoma (EA) is the sixth most common cause of global cancer death. We rely on end...
Barrett's oesophagus normally affects the distal oesophagus when metaplastic columnar lined epitheli...
AIM: Our main objectives were to evaluate the influence of two-year proton pump inhibitors (PPI) the...
Background: Treatment of dysplastic Barrett's oesophagus prevents progression to adenocarcinoma; how...
Background: Esophageal adenocarcinoma (EAC) has high mortality and is increasing in incidence. Barre...
textabstractObjectives: Non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs...